SAF Scoring Examines Risk Factors in MASLD Disease Severity

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a significant global health burden due to its rising prevalence, leading to adverse outcomes such as liver cirrhosis and hepatocellular carcinoma. Current understanding of MASLD severity and its associated risk factors remains limited, necessitating enhanced evaluation methods to guide clinical management and treatment strategies.

Method: This study utilized a multicenter approach, employing the SAF scoring system to assess histopathological features of MASLD in a diverse cohort of patients. Inclusion criteria encompassed adults diagnosed with MASLD, with histological samples evaluated for specific severity indicators. The study aimed to identify correlations between SAF scores and clinical outcomes.

Results: Preliminary findings revealed that higher SAF scores were associated with increased disease severity, with a notable increase in risk for liver-related complications. Specifically, patients with a SAF score above 3 exhibited a 40% higher prevalence of advanced fibrosis compared to those with lower scores, with adjustments for confounding variables. Safety assessments indicated no significant adverse events related to the histopathological evaluations.

Conclusion: These results underscore the potential of SAF scoring as a critical tool in evaluating MASLD severity, supporting refined treatment strategies. The findings advocate for its integration into routine clinical practice to enhance risk stratification in patients with MASLD. Nonetheless, the study is limited by its cross-sectional design and the need for longitudinal validation with larger cohorts to generalize the findings.

Original citation address: https://www.besjournal.com/en/article/doi/10.3967/bes2026.009